Dr. Saleem Shahzad MD

Recommended Articles

• Hospital-Acquired Pneumonia

  Hospital-acquired pneumonia occurs in patients who have been hospitalized, usually after two to three days of hospital admission. Pneumonia contracted in such a setting is often more severe than a community-acquired pneumonia because the organisms causing it are more aggressive. This means that the...

• How Astrophysics Could Transform the Treatment of Cystic Fibrosis and Other Rare Diseases

  Cystic fibrosis is a genetic disease that mainly affects the lungs, liver, pancreas, intestines, reproductive organs, and sinuses. It causes thick and sticky mucus to accumulate and clog the lungs, making it difficult to breathe and resulting in persistent lung infections and lung damage. The...

• Facts About Asthma That You Should Know

  Breathe in and breathe out. Isn't it one of the simplest things to do in life? But when you see your loved ones, especially your children, wheezing, it can really make you anxious and stressed. One of the most traumatizing diseases that can leave one struggling for something as basic as oxygen is...

• Is Bronchitis a Contagious Disease?

  The human respiratory tract starts at the nose and mouth and continues down to the lungs. The air that we breathe in through our nose and mouth passes down the trachea and into the lungs through a series of branched tubes called the bronchi. For a healthy breathing to happen effectively, these tubes...

• New Lung Cell Type Discovered May Be a Key to Efforts to Cure CF

  After years and years of studying the CFTR (cystic fibrosis transmembrane conductance regulator) gene and progress in the treatment of cystic fibrosis, researchers still have not been able to find a cure for the disease. But now, based on the findings of two independent studies, they are moving one...

• FDA Approves Orkambi to Treat Young Children with Cystic Fibrosis

  Orkambi is an oral drug developed by Vertex Pharmaceuticals and approved by the United States Food and Drug Administration (FDA) for the treatment of cystic fibrosis (CF) in certain patient groups. It is the second drug to be approved for use in patients with CF, after Kalydeco. ...